StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.



Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.